Oscotec Inc.

Translating science into medicine
Sign Up
PRESS
FLT3/AXL Inhibitor (A... 2020.06.22  
  1. YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results

    Date2018-06-03
    Read More
  2. YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results

    Date2018-05-16
    Read More
  3. YH25448, an irreversible 3rd-generation EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLC

    Date2018-04-18
    Read More
  4. Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer

    Date2017-02-16
    Read More
  5. YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival benefit over osimertinib in mice with brain metastases of NSCLC

    Date2016-12-07
    Read More
  6. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs

    Date2016-10-01
    Read More
  7. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors

    Date2015-10-15
    Read More
  8. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia

    Date2014-04-03
    Read More
  9. Crystal Structure of Pim1 Kinase in Complex with a Pyrido[4,3-D]Pyrimidine Derivative Suggests a Unique Binding Mode

    Date2013-07-31
    Read More
Board Pagination Prev 1 Next
/ 1
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.